2017 | 2016 | 2015 | 2014
DateTitle 
May 22, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--May 22, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of June: William Blair 2017 Growth Stock Conference on Wednesday, June 14, 2017 at 10:00 am (CDT) in Chicago; and Nasdaq 36th Investor Program on Thursday, June 15, 2017 at 11:00 am (BST) in London The presentations will... 
Printer Friendly Version
May 17, 2017New Data for Presentation at ASCO 2017 Reinforce Clinical Profile of Epacadostat in Combination with Keytruda® (pembrolizumab)
Incyte’s IDO1 enzyme inhibitor in combination with Merck’s anti-PD-1 therapy is well-tolerated and demonstrates durable clinical responses across multiple solid tumors WILMINGTON, Del.--(BUSINESS WIRE)--May 17, 2017-- Incyte Corporation (Nasdaq:INCY) today announced the publication of new data from the ongoing ECHO-202 trial, evaluating epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Keytruda® (pembrolizumab), Merck’... 
Printer Friendly Version
May 17, 2017First Data from Combination of Epacadostat with Opdivo® (nivolumab) Will Be Highlighted at ASCO 2017
Combination is well-tolerated and demonstrates promising clinical outcomes in multiple advanced solid tumors WILMINGTON, Del.--(BUSINESS WIRE)--May 17, 2017-- Incyte Corporation (Nasdaq:INCY) today announced that the American Society of Clinical Oncology (ASCO) has published Phase 1/2 data from the ongoing ECHO-204 trial evaluating the safety and efficacy of epacadostat, Incyte’s selective IDO1 enzyme inhibitor, in combination with Opdivo® (ni... 
Printer Friendly Version
May 04, 2017Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs
$251 million of 2017 first-quarter net product revenues from Jakafi® (ruxolitinib), representing 37 percent growth over the same period last year Expanded ECHO program for epacadostat to include multiple pivotal trials in patients with melanoma, non-small cell lung, head & neck, bladder, and renal cancers in combination with PD-1 inhibitors Olumiant® (baricitinib) approved by the European Commissio... 
Printer Friendly Version
April 25, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 25, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of May: Bank of America Merrill Lynch 2017 Health Care Conference on Wednesday, May 17, 2017 at 10:00 am (PDT) in Las Vegas; and UBS Global Healthcare Conference on Monday, May 22, 2017 at 11:30 am (EDT) in New York The... 
Printer Friendly Version
April 20, 2017Incyte's Immuno-oncology and Targeted Therapy Clinical Portfolio to be Featured in More than 15 Abstracts at the 2017 ASCO Annual Meeting
Presentations to include data from the ECHO-202 trial of epacadostat plus KEYTRUDA® (pembrolizumab) and initial data from the ECHO-204 trial of epacadostat plus Opdivo® (nivolumab) WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 20, 2017-- Incyte Corporation (Nasdaq: INCY) announces that more than 15 abstracts highlighting its research and development portfolio in immuno-oncology and targeted therapies will be presented at the upcoming 2017 American ... 
Printer Friendly Version
April 18, 2017Incyte to Report First Quarter Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Apr. 18, 2017-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 10:00 a.m. ET on Thursday, May 4, 2017. The schedule for the press release and conference call/webcast is as follows: • Q1 2017 Press Release:   ... 
Printer Friendly Version
April 14, 2017U.S. FDA Issues Complete Response Letter for Baricitinib
INDIANAPOLIS--(BUSINESS WIRE)--Apr. 14, 2017-- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for the New Drug Application (NDA) of the investigational medicine baricitinib, a once-daily oral medication for the treatment of moderate-to-severe rheumatoid arthritis (RA). This Smart News Release features multimedia. View the full r... 
Printer Friendly Version
April 02, 2017Bristol-Myers Squibb and Incyte to Advance the Combination of Opdivo (nivolumab) and Epacadostat into First-line Registrational Trials
Companies to initiate Phase 3 registrational trials in first-line non-small cell lung cancer across the spectrum of PD-L1 expression and first-line head and neck cancer in 2017 Collaboration will add additional I-O relapsed/refractory melanoma cohorts to ECHO-204, the ongoing Phase 1/2 multi-tumor study of epacadostat plus Opdivo NEW YORK & WILMINGTON, Del.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) and Incyte Corporation (Na... 
Printer Friendly Version
March 31, 2017Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)
Clinical Program Now Includes Seven Registrational Trials Across Five Tumor Types WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Mar. 31, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, wit... 
Printer Friendly Version
March 02, 2017Incyte’s Targeted Therapy and Immuno-oncology Portfolio to be Featured in 20 Abstracts at the AACR Annual Meeting 2017
WILMINGTON, Del.--(BUSINESS WIRE)--Mar. 2, 2017-- Incyte Corporation (Nasdaq:INCY) announces that 20 abstracts from its research and development portfolio will be presented at the upcoming 2017 American Association for Cancer Research (AACR) annual meeting in Washington, D.C. from April 1-5, 2017. These abstracts include a clinical data presentation from the dose-escalation phase of the Company’s ongoing trial of its selective FGFR 1/2/3 inhibitor ... 
Printer Friendly Version
February 28, 2017Incyte Raises Awareness for Myeloproliferative Neoplasms as Part of Rare Disease Day 2017
February 28, 2017, commemorates the tenth annual Rare Disease Day Incyte supports efforts to raise awareness and improve diagnosis and treatment for the nearly 200,000 people in the United States with MPNs, a group of rare blood cancers WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 28, 2017-- Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURODI... 
Printer Friendly Version
February 23, 2017Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania
Collaboration aims to advance the understanding of cancer biology and foster innovative science in immunotherapy WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 23, 2017-- Incyte Corporation (Nasdaq:INCY) today announces a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania. Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug dis... 
Printer Friendly Version
February 21, 2017Incyte to Present at Upcoming Investor Conferences
WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 21, 2017-- Incyte Corporation (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of March: Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8, 2017 at 10:00 am (EST) in Boston; and Barclays Capital Global Healthcare Conference on Wednesday, March 15, 2017 at 2:35 pm (EDT) in Miami ... 
Printer Friendly Version
February 15, 2017Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo
INDIANAPOLIS ,Feb. 15, 2017/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today additional detailed results from RA-BEAM – a pivotal phase 3 study of baricitinib in the treatment of moderate-to-severe rheumatoid arthritis (RA) – were published in the New England Journal of Medicine.The New England Journal of Medicine publication includes supplementary data, which show that starting as early as week 8, and sustained through week 52, a h... 
Printer Friendly Version
February 14, 2017Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs
$238 million of 2016 fourth-quarter net product revenues from Jakafi® (ruxolitinib), representing 30 percent growth over the same period last year and $853 million of 2016 full-year net product revenues from Jakafi, representing 42 percent growth over last year Multiple pivotal programs expected to commence this year, including the combination of epacadostat and pembrolizumab in four additional solid tumor indications ... 
Printer Friendly Version
February 14, 2017Incyte and Agenus Amend Collaboration Agreement
Incyte secures global clinical development and commercialization responsibilities for GITR and OX40 programs, converting both from profit-sharing to royalty-bearing arrangements Agenus to receive $80 million from Incyte: $60 million equity investment at $6 per share and $20 million in accelerated clinical development milestones WILMINGTON, Del. & LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 14, 2017-- Incyte Corporation (Nasdaq:INCY) an... 
Printer Friendly Version
February 13, 2017European Commission Approves Once-Daily Olumiant Tablets for Treatment of Adults with Moderate-to-Severe Active Rheumatoid Arthritis
Baricitinib, marketed as Olumiant, is the first JAK inhibitor approved to treat RA in the EU INDIANAPOLIS, Feb. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or w... 
Printer Friendly Version
January 30, 2017Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor
Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158 Calithera conference call scheduled... 
Printer Friendly Version
January 24, 2017Incyte to Report Fourth Quarter and Year-End Financial Results
WILMINGTON, Del.--(BUSINESS WIRE)--Jan. 24, 2017-- Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its fourth quarter and year end 2016 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, February 14, 2017. The schedule for the press release and conference call/webcast is as follows:      ... 
Printer Friendly Version
January 13, 2017U.S. FDA Extends Review Period for Baricitinib, an Investigational Rheumatoid Arthritis Treatment
INDIANAPOLIS, Jan. 13, 2017 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced today that the U.S. Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA). The NDA for baricitinib was submitted to the FDA in January 2016.The FDA extended the action date to allow time to review ... 
Printer Friendly Version
January 09, 2017Incyte and Merck to Advance Clinical Development Program Investigating the Combination of Epacadostat with KEYTRUDA® (pembrolizumab)
Additional pivotal studies evaluating Incyte’s IDO1 inhibitor in combination with Merck’s anti-PD-1 therapy in patients with non-small cell lung, renal, bladder and head and neck cancers expected to start in 2017 WILMINGTON, Del. & KENILWORTH, N.J.--(BUSINESS WIRE)--Jan. 9, 2017-- Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the decision to advance the clinical de... 
Printer Friendly Version
RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet